lisdexamfetamine + d-amphetamine

The combination of lisdexamfetamine and d-amphetamine in this context refers to a comparative pharmacological study (LisDexStudy, NCT02668926) conducted by the University Hospital Basel, Switzerland. Lisdexamfetamine is a prodrug consisting of d-amphetamine covalently linked to the amino acid L-lysine; it is pharmacologically inactive until it is enzymatically hydrolyzed, primarily by red blood cells, to release active d-amphetamine. D-amphetamine is a potent central nervous system stimulant that increases the synaptic concentrations of dopamine and norepinephrine. It achieves this by inhibiting the reuptake of these monoamines through the dopamine transporter (DAT) and norepinephrine transporter (NET), promoting their release from presynaptic neurons, and acting as an agonist at the trace amine-associated receptor 1 (TAAR1). The study specifically compared the acute emotional, endocrine, and pharmacokinetic profiles of these two formulations in healthy subjects to evaluate differences in onset, duration of action, and potential for misuse in the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Brand names

VyvanseElvanseDexedrineZenzediProCentra

Other names

lisdexamfetamine dimesylated-amphetamine sulfatedextroamphetamined-amphetamine